A Participant- and Investigator--Blinded, Placebo-Controlled, Randomized, Multipart, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants with Chronic Kidney Disease

2025-520978-18-00 Protocol COJR520A12101 Human pharmacology (Phase I) - First administration to humans Authorised, recruitment pending

Status Authorised, recruitment pending · 2 EU/EEA countries · 3 sites · Protocol COJR520A12101

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Authorised, recruitment pending
Participants planned 124
Countries 2
Sites 3

Chronic Kidney Disease

Key facts

Sponsor
Novartis Pharma AG
Participant type
Healthy volunteers, Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Male Urogenital Diseases [C12], Diseases [C] - Female Urogenital Diseases and Pregnancy Complications [C13]
Decision date (initial)
2026-02-10
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2025-520978-18-00
WHO UTN
U1111-1327-9750

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Chronic Kidney Disease

VersionLevelCodeTermSystem organ class
23.1 PT 10064848 Chronic kidney disease 100000004857

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Novartis Pharma AG

Sponsor organisation
Novartis Pharma AG
Address
Lichtstrasse 35
City
Basel
Postcode
4056
Country
Switzerland

Scientific contact point

Organisation
Novartis Pharma AG
Contact name
Novartis Pharma Arzneimittel GmbH

Public contact point

Organisation
Novartis Pharma AG
Contact name
Novartis Pharma Arzneimittel GmbH

Locations

2 EU/EEA countries · 3 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Authorised, recruitment pending 12 1
Romania Authorised, recruitment pending 32 2
Rest of world
United States
80

Investigational sites

Germany

1 site · Authorised, recruitment pending
Charite Research Organisation GmbH
#2000: Pruefzentrum, Chariteplatz 1, Mitte, Berlin

Romania

2 sites · Authorised, recruitment pending
Spitalul Clinic Judetean De Urgenta Cluj
3002: Internal Medicine, Strada Clinicilor 3-5, 400006, Cluj-Napoca
Arensia Clinics S.R.L.
3001: Nephrology, Intrarea Tudor Stefan 38-40, 011658, Bucharest

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-10-14 Romania Acceptable
2026-02-09
2026-02-10
2 NON SUBSTANTIAL MODIFICATION NSM-1 2026-02-20 Romania Acceptable
2026-02-09
2026-02-20
3 NON SUBSTANTIAL MODIFICATION NSM-2 2026-03-25 Acceptable
2026-02-09
2026-03-25